News | Image Guided Radiation Therapy (IGRT) | August 07, 2017

Early Clinical Experience with ViewRay's MRIdian Linac Presented at AAPM 2017

Talks highlight clinical value of MRIdian on-table adaptive therapy for escalating target dose and avoiding nearby organs at risk

August 7, 2017 — ViewRay Inc. announced that several presentations of early clinical experience with its MRIdian Linac technology were made at the 2017 annual meeting of the American Association of Physicists in Medicine (AAPM), July 30-Aug. 2 in Denver. MRIdian Linac is the world’s only U.S. Food and Drug Administration (FDA)-cleared magnetic resonance imaging (MRI)-guided radiation therapy system with linear accelerator-based delivery, according to the company.

The company's MRIdian System was the focus of 30 abstracts selected by AAPM, including several talks describing the significant advantages of daily on-table adaptive radiation therapy and its positive clinical impact on treatment. MR-guided on-table adaptive therapy allows for dose escalation for stereotactic body radiation therapy (SBRT) treatments and dose de-escalation in cases where the critical structures are too close to the tumor. 

The AAPM Scientific Session talks also highlighted MRIdian's fully integrated workflow for adaptive therapy, which incorporates complete Monte Carlo dose replanning to account for changes in the shape and position of the tumor and adjacent organs in less than two minutes.

ViewRay featured a number of presentations in the company's booth given by MRIdian users from five top cancer centers: Henry Ford Health System in Metro Detroit; University of California, Los Angeles; Washington University in St. Louis; University of Wisconsin; and University of Miami.

Highlights from these talks included:

  • Carri Glide-Hurst, Ph.D., from Henry Ford presented on their initial patient experience with MRIdian Linac including treatment times of 6.25 minutes for 8Gy SBRT treatments and 5 minutes for prostate intensity modulated radiation therapy (IMRT) treatments. She also showed MRIdian movies on how the system's real-time imaging during treatment automatically detected and paused the treatment when a transient gas bubble shifted the prostate. Additional patients in the queue for Henry Ford include liver SBRT, retroperitoneal SBRT and accelerated partial breast irradiation (APBI). "MRIdian really does take the blindfold off in showing us things we've never seen before," said Glide-Hurst. "We're now able to treat indications that we hadn't really treated previously like APBI. We're excited about the potential of reducing margins and getting a conformal delivery with MRI guidance";
  • Anthony Doemer, M.S., from Henry Ford highlighted the ultra-sharp beam characteristics for the RayZR Double focused multileaf collimator (MLC). Because of its design, it removes the need for tongue and grooves, nearly eliminating any leakage through the leaves (average leakage, less than 0.001 percent). "We were able to successfully commission the MLC with great agreement between measured small beam profiles of 0.2 x 0.4 cm and larger profiles matching very well with the Monte Carlo simulations with tight conformance to the beam model," said Doemer;
  • Yingli Yang, Ph.D., from UCLA presented on MRIdian's high-quality MRI images, specifically the superior soft-tissue image quality enabled by MRIdian's processing techniques. Yang also highlighted early research imaging results acquired using a new MR acquisition technique reducing the imaging times of 17 seconds down to approximately 12 seconds. This 3-D MRI sequence provides motion artifact-free images with a large field of view (FOV) for short breath hold. She also presented research on a 3-D MRI acquisition scheme that is insensitive to motion and will enable free breathing MRI for patients who are unable to hold their breath;
  • Vivian Rodriguez, Ph.D., from Washington University shared their extensive experience with on-table adaptive therapy, illustrating the significant anatomical changes that can take place within a short period of time and highlighting case examples where the treatment plan was reoptimized to escalate or de-escalate dose based upon the proximity of nearby critical structures while the patient was on the treatment table. "With a single button click we can replan within a minute a new treatment plan that reduces dose to organs at risk while giving a greater dose to the target," said Rodriguez; and
  • Kathryn Mittauer, Ph.D., from the University of Wisconsin shared their experience personalizing patient treatments through daily dose-guided radiotherapy using online recalculation and evaluation of the actual dose distribution. "We're able to deliver higher doses to targets adjacent to organs at risk due to improved confidence in treatment set up and delivery that would not otherwise be clinically feasible," said Mittauer.

For more information: www.viewray.com

 

Related Articles on MRI-guided Radiation Therapy:

MRI-guided Radiation Therapy (2017)

First Patients Treated with ViewRay's MRIdian Linac at Henry Ford Health System

Elekta Begins MR-Linac Installation at Sunnybrook Health Sciences Centre

MRI-Guided Radiation Therapy (2016)

MRI Brings New Vision to Radiation Therapy

Dutch Medical Center Begins Installation of World's First High-field MRI-guided Radiation Therapy System

Related Content

Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...